About
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to transforming the landscape of kidney disease treatment, particularly in addressing hyperphosphatemia and its associated disorders. With its innovative pipeline aimed at regulating phosphorus levels through unique therapeutic mechanisms, Unicycive seeks to improve patient outcomes significantly. The company's strong focus on research and development, coupled with strategic collaborations, positions it well to lead advancements in nephrology care. As Unicycive progresses through its clinical trials, it presents a compelling investment opportunity for institutional investors looking to capitalize on growth in the evolving healthcare sector.
Advanced charting, extended hours trading, and free stock for new accounts.
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.